Turedi Ozlem, Sozener Zeynep Celebi, Kendirlinan Resat, Bavbek Sevim
Department of Medical Genetics, Ankara University School of Medicine, Ankara. Turkey.
Department of Pulmonary Disease, Ankara University School of Medicine, Division of Allergy and Clinical Immunology, Ankara. Turkey.
Curr Drug Saf. 2017;12(3):198-200. doi: 10.2174/1574886312666170711122341.
Hypersensitivity reactions due to Proton pump inhibitors (PPIs ) are rare, and further anaphylaxis to a PPI with cross-reactivity to all commercially available PPIs is very rare.
To present a case of anaphylaxis to pantoprazole with cross-reactivity to all commercially available PPIs.
Skin prick tests (SPTs), intradermal tests (IDTs) and oral provocation tests (OPTs) were performed with available PPIs according to the method described in previous studies.
All tested PPIs except lansoprazole were positive on skin tests either SPT or IDT. The patient was challenged with lansoprazole at increasing doses (7.5 mg, 15 mg, 30 mg capsule) every 60 minutes and she reacted with urticaria to 52.5 mg cumulative dose of lansoprazole. She could tolerate ranitidine and famotidine tablets via OPT.
In our best knowledge, our case was the first case in this regard and that points the possibility of all cross-reactive pattern in patients with pantoprazole anaphylaxis and the importance of a thorough drug allergy work-up for finding safe alternatives. H2 receptor antagonists are used as safe alternatives in cases with PPI hypersensitivity.
质子泵抑制剂(PPIs)引起的超敏反应罕见,而对一种PPI发生过敏反应且与所有市售PPIs存在交叉反应的情况则极为罕见。
报告一例对泮托拉唑过敏且与所有市售PPIs存在交叉反应的病例。
按照既往研究中描述的方法,使用可用的PPIs进行皮肤点刺试验(SPTs)、皮内试验(IDTs)和口服激发试验(OPTs)。
除兰索拉唑外,所有受试PPIs的皮肤试验(SPT或IDT)均呈阳性。患者每60分钟接受递增剂量(7.5mg、15mg、30mg胶囊)的兰索拉唑激发试验,累积剂量达52.5mg时出现荨麻疹反应。通过口服激发试验,她能够耐受雷尼替丁和法莫替丁片。
据我们所知,我们的病例是这方面的首例,这表明泮托拉唑过敏患者可能存在所有交叉反应模式,以及进行全面药物过敏检查以寻找安全替代药物的重要性。在PPI超敏反应的病例中,H2受体拮抗剂可作为安全的替代药物。